Du är här

2014-05-20

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 20 May 2014 -
Ablynx[Euronext Brussels: ABLX]

today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from Biotech Value
Fund Partners LP and Biotech Value Fund Inc.

Biotech Value Fund Partners LP and Biotech Value Fund Inc notified that they
have dropped below the 5% threshold (from 5.23% to 4.93%) and now hold
2,417,991 Ablynx shares of the current 49,083,327 outstanding shares of
Ablynx.

Full versions of all transparency notifications are available on the website
of Ablynx, under the sectionInvestors.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the discovery and development
ofNanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has more than30 programmes in the pipelineand seven Nanobodies in clinical
development. Ablynx has on-going research collaborations and significant
partnerships with companies including AbbVie, Boehringer Ingelheim, Merck&Co,
Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.

More information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

pdf version of the press release
http://hugin.info/137912/R/1787358/613665.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1787358

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.